Related references
Note: Only part of the references are listed.Effects of 15-deoxy-Δ12, 14 prostaglandin J2 and ciglitazone on human cancer cell cycle progression and death:: The role of PPARγ
Valeria Ferreira-Silva et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Ramya Kapadia et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Antitumorigenic effects of peroxisome proliferator-activated receptor-γ in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-κB
Yvette Bren-Mattison et al.
MOLECULAR PHARMACOLOGY (2008)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
15-Deoxy-Δ12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes:: Role of NF-κB and early growth response transcription factors
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2007)
Activation of peroxisome proliferator-activated receptor γ contributes to the survival of T lymphoma cells by affecting cellular metabolism
Chunyan Yang et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers
Lisa D. Yee et al.
CLINICAL CANCER RESEARCH (2007)
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents
Kudret Tureyen et al.
JOURNAL OF NEUROCHEMISTRY (2007)
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
Electron Kebebew et al.
SURGERY (2006)
Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times
Glen Kristiansen et al.
CLINICAL CANCER RESEARCH (2006)
Peroxisome proliferator-activated receptor γ promotes lymphocyte survival through its actions on cellular metabolic activities
Seung-Hee Jo et al.
JOURNAL OF IMMUNOLOGY (2006)
Altered PPARγ expression and activation after transient focal ischemia in rats
N. A. Victor et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway
Y Kato et al.
ONCOGENE (2006)
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
YM Luo et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation
TJ Giordano et al.
CLINICAL CANCER RESEARCH (2006)
Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice
K Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation
MJ Betz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma
T Masuda et al.
CLINICAL CANCER RESEARCH (2005)
Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice
J Lu et al.
CANCER RESEARCH (2005)
Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production
JN Hwang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells
KL Schaefer et al.
CANCER RESEARCH (2005)
Peroxisome proliferator-activated receptor γ is a novel target of the nerve growth factor signaling pathway in PC12 cells
KM Fuenzalida et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma
GY Zhang et al.
BRITISH JOURNAL OF CANCER (2005)
Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia
S Sundararajan et al.
NEUROSCIENCE (2005)
Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion
HR Liu et al.
CARDIOVASCULAR RESEARCH (2004)
PPARγ signaling exacerbates mammary gland tumor development
E Saez et al.
GENES & DEVELOPMENT (2004)
A novel antipyretic action of 15-deoxy-Δ12,14-prostaglandin J2 in the rat brain
A Mouihate et al.
JOURNAL OF NEUROSCIENCE (2004)
Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer
VG Keshamouni et al.
ONCOGENE (2004)
PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
CJ Nicol et al.
CARCINOGENESIS (2004)
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
MR Smith et al.
CANCER (2004)
Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates myocardial ischernia/reperfusion injury in a rat model
H Ito et al.
LABORATORY INVESTIGATION (2003)
A phase II trial with rosiglitazone in liposarcoma patients
G Debrock et al.
BRITISH JOURNAL OF CANCER (2003)
Genetic deficiency in Pparg does not alter development of experimental prostate cancer
E Saez et al.
NATURE MEDICINE (2003)
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?
G Gasparini et al.
LANCET ONCOLOGY (2003)
Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ
LC Bell-Parikh et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury
A Sivarajah et al.
AMERICAN JOURNAL OF NEPHROLOGY (2003)
Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
HJ Burstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists
R Yoshimura et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice
E Osawa et al.
GASTROENTEROLOGY (2003)
Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter
GD Girnun et al.
MOLECULAR ENDOCRINOLOGY (2002)
APIC-dependent suppression of colon carcinogenesis by PPARγ
GD Girnun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
MH Kulke et al.
CANCER JOURNAL (2002)
Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival
YL Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size
NS Wayman et al.
FASEB JOURNAL (2002)
Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility
Y Cui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer
Y Segawa et al.
PROSTATE (2002)
Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists
K Inoue et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Peroxisome proliferator-activated receptor γ-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element
JG Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells
K Ohta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
H Sato et al.
BRITISH JOURNAL OF CANCER (2000)
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
E Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma
TG Kroll et al.
SCIENCE (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
A Rossi et al.
NATURE (2000)
Clinical pharmacokinetics of pioglitazone
DA Eckland et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2000)
Share Paper
